Nasdaq:SLNO
SOLENO THERAPEUTICS INC
A clinical-stage biopharma firm developing targeted CNS therapies for severe psychiatric and neurological disorders with a strong pipeline of proprietary assets.
Key Metrics
Investment Thesis
Bull Case
Investors might consider SLNO due to its high-potential pipeline targeting large markets in CNS disorders where current treatments are limited or ineffective. The company's ability to generate positive net income and maintain substantial liquid assets suggests strong financial discipline and potential for milestone-based revenue recognition from partners. A successful catalyst event such as a pivotal Phase 3 trial reading could significantly re-rate the stock valuation upward.
Bear Case
The stock carries elevated risk given the history of large operating losses in previous years and the inherent uncertainty of clinical-stage biopharmaceutical development. With a retained earnings deficit exceeding $431M, the company relies heavily on future financing to fund its extensive research and development programs without guaranteed commercial returns. Any failure in upcoming clinical trials or delays in regulatory approval could lead to further dilution or liquidity constraints for shareholders.
About SOLENO THERAPEUTICS INC
SOLENO Therapeutics Inc (SLNO) is a clinical-stage biopharmaceutical company focused on developing novel treatments for central nervous system disorders. The company leverages its extensive pipeline of proprietary small molecules targeting conditions like epilepsy, schizophrenia, and major depressive disorder. With a diverse portfolio of assets in development across multiple therapeutic areas, SLNO aims to address significant unmet needs in the global healthcare market.
Analysis
Management Discussion
The company reported a significant turnaround in net income for the latest period, showing $20.9M profit compared to substantial losses in prior years, driven largely by non-cash adjustments and strategic financial management. However, operating expenses remain high at $181.0M due to ongoing intensive R&D efforts totaling $40.6M, reflecting the capital-intensive nature of clinical-stage biopharma development. The balance sheet shows healthy cash reserves of $70.1M alongside long-term marketable securities of $200.6M, providing a buffer for continued research activities despite the recent net change in cash decline.
Industry Overview
The global biopharmaceutical industry is experiencing robust growth driven by an aging population and increasing prevalence of neurological and psychiatric disorders. Competition is fierce among large pharmaceutical companies and specialized biotechs, but differentiation through innovative mechanisms of action remains a key value driver. Regulatory pathways in the US and EU are becoming more streamlined for orphan drugs and rare disease indications, offering accelerated approval opportunities.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $190.4M |
| Cost of Revenue | $0 | $0 | $0 | $2.7M |
| Gross Profit | $0 | $0 | $0 | $187.7M |
| Operating Expenses | $24.4M | $41.4M | $187.7M | $181.0M |
| Operating Income | $-24.4M | $-41.4M | $-187.7M | $9.4M |
| R&D | $15.3M | $25.2M | $78.6M | $40.6M |
| G&A | $9.8M | $13.5M | $105.9M | $132.1M |
| Stock-Based Comp | $2.5M | $5.9M | $100.0M | $45.8M |
| D&A | $2.0M | $2.0M | $2.0M | $2.0M |
| Depreciation | $20.0K | $14.0K | $43.0K | $73.0K |
| Other OpEx | $-712.0K | $2.7M | $3.2M | $8.2M |
| Non-Operating Income | $330.0K | $2.4M | $11.8M | $11.5M |
| Interest Income | — | — | $12.1M | $17.0M |
| Pre-Tax Income | $-24.1M | $-39.0M | $-175.8M | $20.9M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-24.1M | $-39.0M | $-175.8M | $20.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-24.1M | $-39.0M | $-175.8M | $20.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-24.1M | $-39.0M | $-175.8M | $20.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $15.6M | $171.4M | $293.9M | $355.8M |
| Cash & Equivalents | $14.6M | $169.7M | $87.9M | $70.1M |
| Marketable Securities | — | — | $203.5M | $235.4M |
| Accounts Receivable | — | — | — | $28.2M |
| Inventory | — | — | — | $15.0M |
| Prepaid Expenses | $1.0M | $1.7M | $2.5M | $7.1M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $10.8M | $9.3M | $37.1M | $208.0M |
| PP&E (Net) | $26.0K | $12.0K | $186.0K | $185.0K |
| Intangibles | $10.7M | $8.7M | $6.8M | $4.9M |
| Operating Leases | $131.0K | $407.0K | $2.8M | $2.2M |
| LT Securities | — | — | $27.2M | $200.6M |
| Other LT Assets | $0 | $165.0K | $83.0K | $163.0K |
| Total Assets | $26.5M | $180.7M | $331.0M | $563.8M |
| Current Liabilities | $7.3M | $11.5M | $18.7M | $61.4M |
| Accounts Payable | $1.8M | $3.1M | $8.9M | $12.4M |
| Current Leases | $155.0K | $273.0K | $526.0K | $726.0K |
| Other Current Liab | $5.4M | $8.1M | $9.3M | $48.2M |
| Long-Term Liabilities | $8.8M | $11.7M | $67.1M | $52.4M |
| Long-Term Debt | — | — | $49.8M | $49.9M |
| LT Operating Leases | $0 | $130.0K | $2.5M | $2.0M |
| Other LT Liab | $8.8M | $11.5M | $14.8M | $525.0K |
| Total Liabilities | $16.1M | $23.2M | $85.9M | $113.7M |
| Shareholders' Equity | $10.3M | $157.5M | $245.1M | $450.1M |
| Retained Earnings | $-237.4M | $-276.4M | $-452.3M | $-431.4M |
| AOCI | — | — | $361.0K | $415.0K |
| Total L&E | $26.5M | $180.7M | $331.0M | $563.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-24.1M | $-39.0M | $-175.8M | $20.9M |
| Non-Cash Adjustments | $3.8M | $9.3M | $97.5M | $-43.4M |
| Working Capital Changes | $-482.0K | $4.7M | $9.3M | $69.3M |
| Cash from Operations | $-20.8M | $-24.9M | $-69.1M | $46.8M |
| Capital Expenditures | $13.0K | $0 | $218.0K | $73.0K |
| Cash from Investing | $-13.0K | $0 | $-225.7M | $-201.8M |
| Debt Issuances | — | — | $49.9M | $0 |
| Share Buybacks | — | — | — | $100.1M |
| Cash from Financing | $14.1M | $180.0M | $213.0M | $137.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-6.7M | $155.1M | $-81.8M | $-17.8M |
| Beginning Cash | $21.3M | $14.6M | $169.7M | $87.9M |
| Ending Cash | $14.6M | $169.7M | $87.9M | $70.1M |
Frequently Asked Questions
How does SOLENO THERAPEUTICS INC make money?
The company's revenue is primarily derived from its strategic partnerships and licensing agreements that fund the development and commercialization of its central nervous system (CNS) drug candidates. Financials indicate significant investment in research and development, with operating expenses heavily weighted towards R&D activities for epilepsy, schizophrenia, and depression indications rather than traditional diversified product sales.
What are the main risks for SLNO?
1. High dependence on successful completion of costly and time-consuming Phase 2 and Phase 3 clinical trials which could fail at any stage. 2. Significant cash burn from R&D operations requiring substantial future equity or debt financing if milestones are not met. 3. Potential loss of key patents or regulatory delays by the FDA impacting the commercialization timeline of critical assets.
What is SLNO's competitive advantage?
1. Proprietary intellectual property portfolio protecting a wide range of CNS mechanisms of action including sigma-1 receptor antagonism. 2. Strong strategic partnerships providing upfront payments and milestone funding that reduce near-term capital expenditure burdens. 3. Experienced management team with a proven track record in advancing complex neuroscience assets through clinical trials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.